Petri Anette Lykke, Høgdall Estrid, Engelholm Svend Aage, Christensen Ib Jarle, Kjaer Susanne Krüger, Høgdall Claus K
Rigshospitalet, Juliane Marie Centret, Gynaekologisk Klinik 4232, København Ø.
Ugeskr Laeger. 2007 Aug 13;169(33):2614-9.
New non-invasive diagnostic tests for detection of ovarian cancer in early stages can improve survival. One approach is the proteomic analysis of serum or urine, which may be the technology needed. Preliminary proteomic analyses of serum and urine have shown a higher positive predictive value than that of the combination of serum CA125 and ultrasound examination, which actually is used preoperatively for the ovarian cancer diagnosis (RMI index). Identification of new ovarian cancer biomarkers will optimally be usable as an ovarian cancer-screening tool.
用于早期检测卵巢癌的新型非侵入性诊断测试可提高生存率。一种方法是对血清或尿液进行蛋白质组分析，这可能正是所需的技术。血清和尿液的初步蛋白质组分析显示，其阳性预测值高于血清CA125和超声检查相结合的方法，而后者实际上是术前用于卵巢癌诊断的（RMI指数）。鉴定新的卵巢癌生物标志物将最有可能用作卵巢癌筛查工具。
